## Validation of the revised international prognostic score thrombocythemia (<scp>IPSET</scp>â€ŧhrombosis) in

American Journal of Hematology 91, 390-394 DOI: 10.1002/ajh.24293

**Citation Report** 

CITATION REDORT

#	Article	IF	CITATIONS
1	Refining prognostication of thrombosis in <scp>ET</scp> . American Journal of Hematology, 2016, 91, 361-363.	4.1	8
2	Molecular biomarkers of thrombosis in myeloproliferative neoplasms. Thrombosis Research, 2016, 140, S71-S75.	1.7	28
3	Occurrence of JAK2V617F mutation in previously triple negative essential thrombocythemia. Leukemia and Lymphoma, 2017, 58, 503-504.	1.3	1
4	Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery. Leukemia and Lymphoma, 2017, 58, 2786-2798.	1.3	17
5	Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with essential thrombocythemia. Experimental and Therapeutic Medicine, 2017, 13, 947-951.	1.8	3
6	Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era. Leukemia, 2017, 31, 1845-1854.	7.2	25
7	Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?. British Journal of Haematology, 2017, 176, 352-364.	2.5	23
8	Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature. Current Hematologic Malignancy Reports, 2017, 12, 397-405.	2.3	9
9	Genetic Risk Assessment in Myeloproliferative Neoplasms. Mayo Clinic Proceedings, 2017, 92, 1283-1290.	3.0	53
10	Pregnancy and myeloproliferative neoplasms : A retrospective monocentric cohort. Obstetric Medicine, 2017, 10, 165-169.	1.1	10
11	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia, 2018, 32, 1057-1069.	7.2	415
12	Essential thrombocythemia treatment algorithm 2018. Blood Cancer Journal, 2018, 8, 2.	6.2	85
13	SOHO State-of-the-Art Update and Next Questions: MPN. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 1-12.	0.4	7
14	Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. Journal of Clinical Oncology, 2018, 36, 3361-3369.	1.6	54
15	Emerging therapies for the treatment of essential thrombocythemia. Expert Opinion on Orphan Drugs, 2018, 6, 567-575.	0.8	0
16	JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy. Hematology American Society of Hematology Education Program, 2018, 2018, 110-117.	2.5	7
17	Validation of previous prognostic models for thrombosis and exploration of modified models in patients with essential thrombocythemia. European Journal of Haematology, 2018, 101, 508-513.	2.2	10
18	Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Cancer Treatment and Research, 2019, 179, 159-178.	0.5	16

CITATION REPORT

#	Article	IF	CITATIONS
19	Comparison between thrombotic risk scores in essential thrombocythemia and survival implications. Hematological Oncology, 2019, 37, 434-437.	1.7	10
20	Age at diagnosis is an important prognostic factor in Philadelphiaâ€negative Myeloproliferative Neoplasms. European Journal of Haematology, 2019, 103, 140-141.	2.2	0
21	The Role of New Technologies in Myeloproliferative Neoplasms. Frontiers in Oncology, 2019, 9, 321.	2.8	37
22	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clinic Proceedings, 2019, 94, 599-610.	3.0	103
23	Developments in diagnosis and treatment of essential thrombocythemia. Expert Review of Hematology, 2019, 12, 159-171.	2.2	11
24	From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. Hematology American Society of Hematology Education Program, 2019, 2019, 397-406.	2.5	17
25	Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Advances, 2019, 3, 1729-1737.	5.2	105
26	From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. Blood, 2019, 134, 1902-1911.	1.4	20
27	Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study. Hematology Reports, 2019, 11, 8281.	0.8	17
28	Essential Thrombocythemia. New England Journal of Medicine, 2019, 381, 2135-2144.	27.0	106
29	High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. Annals of Hematology, 2019, 98, 93-100.	1.8	24
30	High red blood cell distribution width might predict thrombosis in essential thrombocythemia and polycythemia vera. Blood Cells, Molecules, and Diseases, 2020, 80, 102368.	1.4	14
31	<p>Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data</p> . OncoTargets and Therapy, 2020, Volume 13, 12367-12382.	2.0	39
32	Correlation Between PAI-1 Gene 4G/5G Polymorphism and the Risk of Thrombosis in Ph Chromosome-Negative Myeloproliferative Neoplasms. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962093520.	1.7	4
33	Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, riskâ€stratification and management. American Journal of Hematology, 2020, 95, 1599-1613.	4.1	204
34	Thrombocytosis and Thrombosis: Is There Really a Correlation?. Current Hematologic Malignancy Reports, 2020, 15, 261-267.	2.3	14
35	Essential thrombocythemia: a hemostatic view of thrombogenic risk factors and prognosis. Molecular Biology Reports, 2020, 47, 4767-4778.	2.3	6

ARTICLE IF CITATIONS # Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and 37 1.6 24 polycythemia vera. International Journal of Hematology, 2020, 112, 377-384. Current management strategies for polycythemia vera and essential thrombocythemia. Blood Reviews, 2020, 42, 100714. Essential Thrombocythemia and Acquired von Willebrand Syndrome: The Shadowlands between 39 3.7 18 Thrombosis and Bleeding. Cancers, 2020, 12, 1746. Hyperuricemia might promote thrombosis in essential thrombocythemia and polycythemia vera. Leukemia and Lymphoma, 2020, 61, 1744-1747. Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood Cancer 41 6.2 35 Journal, 2020, 10, 21. The new WHO classification for essential thrombocythemia calls for revision of available evidences. 6.2 Blood Cancer Journal, 2020, 10, 22. CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK 43 1.3 14 AND SURVIVAL. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020008. The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors. 44 1.0 Advances in Hematology, 2020, 2020, 1-5. Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations. American 45 22 4.1 Journal of Hematology, 2021, 96, 354-366. Successive development of ischemic stroke and hemorrhagic stroke in a patient with essential 1.0 thrombocythemia: a case report. Journal of International Medical Research, 2021, 49, 030006052098771. Antithrombotic Management in Ischemic Stroke with Essential Thrombocythemia: Current Evidence 47 3 2.4 and Dilemmas. Medical Principles and Practice, 2021, 30, 412-421. Manifestações orais nas doenças mieloproliferativas: Uma revisão de literatura. Research, Society and 0.1 Development, 2021, 10, e0710514581. Can Novel Insights into the Pathogenesis of Myeloproliferative Neoplasm-Related Thrombosis Inform 49 0.6 3 Novel Treatment Approaches?. Hemato, 2021, 2, 305-328. Bone Marrow Soluble Mediator Signatures of Patients With Philadelphia Chromosome-Negative 2.8 Myeloproliferative Neoplasms. Frontiers in Oncology, 2021, 11, 665037. Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative 51 1.9 2 Myeloproliferative Neoplasms. Hamostaseologie, 2021, 41, 197-205. Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms. Cells, 2021, 10, 1962. Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in 53 7.0 7 <i>JAK2</i>-Mutated Myeloproliferative Neoplasms. Clinical Cancer Research, 2021, 27, 5708-5717. Comparison of the effects between MPL and JAK2V617F on thrombosis and peripheral blood cell counts 54 in patients with essential thrombocythemia: a meta-analysis. Annals of Hematology, 2021, 100, 1.8 2699-2706.

CITATION REPORT

#	Article	IF	CITATIONS
55	Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. American Journal of Hematology, 2021, 96, 1472-1480.	4.1	20
56	Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm. Korean Journal of Internal Medicine, 2021, 36, 1190-1203.	1.7	9
57	Essential thrombocythemia with portal vein thrombosis and splenic infarction successfully treated with platelet apheresis. BMJ Case Reports, 2021, 14, e245267.	0.5	1
58	Low-Risk Essential Thrombocythemia: A Comprehensive Review. HemaSphere, 2021, 5, e521.	2.7	11
59	Thrombocytosis and thrombosis. Japanese Journal of Thrombosis and Hemostasis, 2021, 32, 383-388.	0.1	0
60	Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25Âyears by the "Ph1â€negative Myeloproliferative Neoplasms Latium Groupâ€: European Journal of Haematology, 2020, 105, 335-343.	2.2	8
61	Essential Thrombocythemia. Molecular Pathology Library, 2018, , 141-154.	0.1	0
62	Pathogenetic mechanisms of thrombosis in patients with myeloproliferative neoplasm. Hematology & Transfusion International Journal, 2018, 6, .	0.1	Ο
63	1. Pathophysiology and Treatment Strategies of Myeloproliferative Neoplasms. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1672-1684.	0.0	0
64	Essential thrombocythemia: Biology, clinical features, thrombotic risk, therapeutic options and outcome. Journal of Hematology and Clinical Research, 2019, 3, 053-059.	0.4	Ο
65	What's in a Number? Examining the Prognostic and Predictive Importance of Platelet Count in Patients With Essential Thrombocythemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1279-1284.	4.9	8
66	Precision Medicine in BCR-ABL1 Negative Myeloproliferative Neoplasms. Healthbook TIMES Oncology Hematology, 2020, , .	0.1	Ο
67	Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities. International Review of Cell and Molecular Biology, 2021, 365, 1-69.	3.2	13
68	The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep. Plasmatology, 2020, 13, 263485352097821.	0.4	22
70	Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH–SETH. Clinical and Translational Oncology, 2022, 24, 770-783.	2.4	1
71	Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. American Journal of Hematology, 2022, 97, E35.	4.1	18
72	Impact of JAK2V617F Mutational on Haematologic Features in Sudanese Patients with Essential Thrombocythemia and Thrombotic Risk Assessment. Journal of Bioscience and Applied Research, 2020, 6, 263-273.	0.2	0
73	JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis. Thrombosis Research, 2022, 211, 1-5.	1.7	6

CITATION REPORT

74Conversity polycythemia were and essential thrombocythemia: management considerations and future1.6577Chinoal and biological relevance of CRBBN 1 in Philadelphia chromosome-negative myeloproliferative0.8078Applied Thrombosity Hemostasis, 2022, 28, 107602962210975.1.7179Validation of themorbosity Hemostasis, 2022, 28, 107602962210975.2.9070Thrombosity Hemostasis, 2022, 28, 107602962210975.2.9070Thrombosity Hemostasis, 2022, 28, 107602962210975.2.9071Applied Thrombosity Instal Journal of Hemostalogy, 2022, 199, 86-94.2.9072Thrombosity Hemostasis, 2022, 28, 107602962210975.2.9073Thrombosity Instal Journal of Hemostalogy, 2022, 199, 86-94.2.9074Thrombosity Instal Journal of Hemostalogy, 2022, 199, 86-94.2.9075Thrombosity Instal Journal of Hemostalogy, 2022, 199, 56-94.2.91.276Thrombosity Instal Journal of Hemostalogy, 2023, 198, 166-179.2.91.278Thrombosity Instal Journal of Hemostalogy, 2023, 98, 166-179.1.3179Relevaluation of cardovascular table factors for threaded and puplication. Chromitol and Applied Thrombosity Installow and Thromboly, 2023, 58, 553-72.1.3179Revealuation of cardovascular table factors for threaded and tymphoma, 2023, 64, 564-572.1.3170Revealuation of cardovascular table factors for threaded and tymphoma, 2023, 64, 564-572.1.3170Revealuation of cardovascular ta	#	Article	IF	CITATIONS
77Clinical and biological relevance of CREBS1 in Philadelphia chronosome-negative myeloproliferative0.8078Appled themorrhagic issues Associated with Myeloproliferative Neoplasms. Clinical and Philadelphia chronososthemostes. 2022, 28. 107002095210797.1.7179Vehication of themorrhagic issues Associated with Myeloproliferative Neoplasms. Clinical and Philadelphia chronososthemostes. 2022, 28. 107002095210797.2.5570Vehication of themorrhagic issues Associated with Myeloproliferative Neoplasms. A multicentre2.5571Triple-Negativity Identifies. Subgroup of Patients with Better Overall Survival in Essential0.8172Advances in Rels Startification and Troatment of Polycythemia Ver and Essential Thrombocythemia.2.31273Thrombosts in Myeloproliferative Neoplasms. A Single Center Experience of Using Whole Blood Philadelphia chromostylemia. American Journal of Hematology, 2022, 19, 466-179.1.12774Leukocytosis and MPNs: Where do we stand?. Leukemia and Lymphoma, 2023, 64, 564-572.1.3175Resealation of cardouscular risk finctors for thromboty cents in S00 spapaese patients with essential thrombocythemia. Journal of Hematology, 2023, 19, 466-179.1.3276Resealation of Cardouscular risk finctors for thromboty cents in S00 spapaese patients with essential thrombocythemia. Journal of Homboosts and Thrombotys, 0,2.1077Negatocytosis in essential thrombocythemia according to three prediction models an external2.1078Resealation of Cardouscular risk finctors for thromboty external abunchagy, 2023, 55, 263-27	74	Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions. Annals of Hematology, 2022, 101, 935-951.	1.8	5
178Thrombotic and Hemorrhagic Issues Associated with Mycloproliferative Neoplasms. Clinical and Applied ThrombosisHemostasis, 2022, 28, 107602362210375.1.1179Validation of thrombotic rish fictors in 1381 patients with essential fromborghasmia: A multicentre recorpective real/stitic study. Betring Jurnal of Hematology, 2022, 199, 86-94.2.06180Thrombosis In Side Stratification and Treatment of Polycythemia Survival In Essential Thrombosis In Side Stratification and Treatment of Polycythemia Vara and Essential Thrombocythemia.2.012181Advances In Side Stratification and Treatment of Polycythemia Vara and Essential Thrombocythemia.2.012182Patient Hematology, Polycit 2022, 17, 155-169.2.012183Thrombosis In Mycloproliferative Neoplasms: A Single Center Experime or Using Whole Blood Hemostasis, 2022, 28, 107602962211174.1.72184Exercise The International Consensus classification of mycloproliferative neoplasms and acter Leukemias: Newledproliferative neoplasms. A Newled neoplasms and acter Leukemias: essential thrombocythemia, Journal of Hemotology, 2023, 98, 166-179.1.12184Leukevytosis and MPNs: Where do we stand?. Leukemia and Lymphoma, 2023, 64, 564-572.1.31184Research, 2022, 58, 537-545.1.31184Statification study. Journal of Thromboste and Thromboste in essential thrombocythemia.2.16184Ottombostis In essential thrombocythemia according to three prediction models: an external selematic thromboste in essential thrombocythemia.2.31184Essental Uberombocythemia, Journal of Thermotoste and Thr	77	Clinical and biological relevance of CREB3L1 in Philadelphia chromosome-negative myeloproliferative neoplasms. Leukemia Research, 2022, , 106883.	0.8	0
170Validation of thrombotic risk factors in 1381 patients with essential thrombocythemia: A multicentre2.6580Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential0.8181Advances in Risk Statification and Irratment of Polycythemia Vera and Essential Thrombocythemia.2.31282Phombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromborphylaxis. Clinical and Applied Thrombosis Hemostasis, 2022, 7, 8, 10760296211174.17283Threintenational concensus dessification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. American Journal of Hematology, 2023, 98, 166-179.1.3184Leukocytosis and MPNs: Where do we stand?. Leukemia and Lymphoma, 2023, 64, 564-572.1.3185Reservaluation of cardiovaecular risk factors for thrombotic events in 580 Japanese patients with validation study. Journal of Thrombosis and Thrombolysis, 2023, 55, 255-272.1.3186Risk of thrombosis in essential thrombocythemia according to three prediction models: an external validation study. Journal of Thrombosis and Thrombolysis, 0,2.1087Pregnosticatori in myeloproliferative neoplasms, Including mutational abnormalities. Blood 442: 448.1.3188Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology. Cells, 422: 448.1.3189Molecular findings in myeloid neoplasms. Including mutational abnormalities. Blood 442: 448.1.3180Cytological Diagn	78	Thrombotic and Hemorrhagic Issues Associated with Myeloproliferative Neoplasms. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210979.	1.7	1
80Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential0.8181Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia.2.32.382Phatent Ageregation Subdies for Risk Assessment and Thromboprophylaxis. Clinical and Applied1.7283Thrombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Thrombosis/Hemostasis, 2022, 28, 107602962211174.1.7284The International consensus classification of myeloid neoplasms and acute Leukemias: Myeloproliferative neoplasms. American Journal of Hematology, 2023, 98, 166-179.1.3184Ecukocytosis and MPNs: Where do we stand?. Leukemia and Lymphoma, 2023, 64, 564-572.1.3185Reesvaluation of cardiovascular risk factors for thrombotyles, 2023, 55, 263-272.2.1486Rescaluation of cardiovascular risk factors for thrombotyles, 2023, 55, 263-272.2.1387Prognostication in myeloproliferative neoplasms, including mutational abnormalities. Blood1.3188Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology. Cells, 2.3489Settsh Journal of Heantology, 2023, 202, 699-703.1.3181Outgetcal Findings in myeloid neoplasms. International Journal of Laboratory Hematology, 2023, 45, 1.31.382Settsh Journal of Heantology, 2023, 202, 699-703.1.31.383Outgetcal Findings in myeloid neoplasms. International Journal of Laboratory Hematology, 2023, 45, 1.31.384 <td>79</td> <td>Validation of thrombotic risk factors in 1381 patients with essential thrombocythaemia: A multicentre retrospective realâ€life study. British Journal of Haematology, 2022, 199, 86-94.</td> <td>2.5</td> <td>5</td>	79	Validation of thrombotic risk factors in 1381 patients with essential thrombocythaemia: A multicentre retrospective realâ€life study. British Journal of Haematology, 2022, 199, 86-94.	2.5	5
11Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia.2.31212Phrombosts in Myeloproliferative Neoplasms A Single Center Experience of Using Whole Blood Thrombosts in Myeloproliferative Neoplasms A Single Center Experience of Using Whole Blood Thrombosts in International consensus classification of myelod neoplasms and acute Leukemias:1.7213The International consensus classification of myelod neoplasms and acute Leukemias: myeloproliferative neoplasms. American Journal of Hematology, 2023, 98, 166-179.1.3114Leukocytosis and MPNs: Where do we stand?. Leukemia and Lymphoma, 2023, 64, 564-572.1.3115Reevaluation of cardiovascular risk factors for thrombotic events in S80 Japanese patients with 	80	Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia. Hematology Reports, 2022, 14, 265-269.	0.8	1
122Thrombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromboprophylaxis. Clinical and Applied1.72133The International consensus classification of myeloid neoplasms and acute Leukemlas: myeloproliferative neoplasms. American Journal of Hematology, 2023, 98, 166-179.1.33144Leukocytosis and MPNs: Where do we stand?. Leukemia and Lymphoma, 2023, 64, 564-572.1.34145Resential thrombocythemia. Journal of Thrombosis and Thrombolysis, 2023, 55, 263-272.2.14146Risk of thrombosis in essential thrombocythemia according to three prediction models: an external validation study. Journal of Thrombosis and Thrombolysis, 0,1.31147Pognostication in myeloproliferative neoplasms, including mutational abnormalities. Blood 	81	Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia. Current Hematologic Malignancy Reports, 2022, 17, 155-169.	2.3	12
183The International consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. American Journal of Hematology, 2023, 98, 166-179.4.127184Leukocytosis and MPNs: Where do we stand?. Leukemia and Lymphoma, 2023, 64, 564-572.1.31185Reevaluation of cardiovascular risk factors for thrombobic events in 580 Japanese patients with essential thrombocythemia. Journal of Thrombosis and Thrombolys, 2023, 55, 263-272.2.14186Risk of thrombostis in essential thrombocythemia according to three prediction models: an external validation study. Journal of Thrombosis and Thrombolysis, 0, .2.10187Prognostication in myeloproliferative neoplasms, including mutational abnormalities. Blood 	82	Thrombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromboprophylaxis. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211174.	1.7	2
184Leukocytosis and MPNs: Where do we stand?. Leukemia and Lymphoma, 2023, 64, 564-572.1.31185Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with validation study. Journal of Thrombosis and Thrombolysis, 2023, 55, 263-272.2.14186Risk of thrombosis in essential thrombocythemia according to three prediction models: an external validation study. Journal of Thrombosis and Thrombolysis, 0,2.10187Prognostication in myeloproliferative neoplasms, including mutational abnormalities. Blood Research, 2023, 58, S37-S45.1.31188Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology. Cells, 2023, 12, 946.4.12190Molecular findings in myeloid neoplasms. International Journal of Laboratory Hematology, 2023, 45, 442-448.1.31191Chrical features and current treatment status of essential thrombocythemia in older adults: a muticenter real-word study in China. Annals of Hematology, 0,1.31192thrombocythemia in Japan. Hematology, 2023, 28, 28, 53, 5461.1.52193The atherogenic index of plasma complicates the thrombotic tendency of chronic myeloproliferative 	83	The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. American Journal of Hematology, 2023, 98, 166-179.	4.1	27
85Reevaluation of cardiovascular risk factors for thrombosis and Thrombolysis, 2023, 55, 263-272.2.1486Risk of thrombosis in essential thrombocythemia according to three prediction models: an external validation study. Journal of Thrombosis and Thrombolysis, 0, .2.1087Prognostication in myeloproliferative neoplasms, including mutational abnormalities. Blood Research, 2023, 58, 537-545.1.3188Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology. Cells, 2023, 12, 946.4.1289(scp> ABO (/scp> blood group type and risk of venous thrombosis in essential thrombocythemia. 	84	Leukocytosis and MPNs: Where do we stand?. Leukemia and Lymphoma, 2023, 64, 564-572.	1.3	1
86Risk of thrombosis in essential thrombocythemia according to three prediction models: an external validation study. Journal of Thrombosis and Thrombolysis, 0, , .2.1087Prognostication in myeloproliferative neoplasms, including mutational abnormalities. Blood Research, 2023, 58, 537-545.1.3188Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology. Cells, o2023, 12, 946.4.1289Scscp>ABO blood group type and risk of venous thrombosis in essential thrombocythemia. British Journal of Haematology, 2023, 202, 699-703.2.5490Molecular findings in myeloid neoplasms. International Journal of Laboratory Hematology, 2023, 45, 442-448.1.8091Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China. Annals of Hematology, 0, ,.1.8092MPL> gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan. Hematology, 2023, 28, 54.093The atherogenic Index of plasma complicates the thrombotic tendency of chronic myeloproliferative disorders: A retrospective cohort study. , 2023, 3, 54-61.0	85	Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia. Journal of Thrombosis and Thrombolysis, 2023, 55, 263-272.	2.1	4
87Prognostication in myeloproliferative neoplasms, including mutational abnormalities. Blood1.3188Cyclological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology. Cells, 2023, 12, 946.4.1289Sscp>ABO blood group type and risk of venous thrombosis in essential thrombocythemia. British Journal of Haematology, 2023, 202, 699-703.2.5490Molecular findings in myeloid neoplasms. International Journal of Laboratory Hematology, 2023, 45, 442-448.1.8091Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China. Annals of Hematology, 0,,1.8092(\>MPL gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan. Hematology, 2023, 28,2.5093The atherogenic Index of plasma complicates the thrombotic tendency of chronic myeloproliferative disorders: A retrospective cohort study. 2023, 3, 5461.0	86	Risk of thrombosis in essential thrombocythemia according to three prediction models: an external validation study. Journal of Thrombosis and Thrombolysis, 0, , .	2.1	0
88Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology. Cells, 2023, 12, 946.4.1289Sscp>ABO blood group type and risk of venous thrombosis in essential thrombocythemia. British Journal of Haematology, 2023, 202, 699-703.2.5490Molecular findings in myeloid neoplasms. International Journal of Laboratory Hematology, 2023, 45, 442-448.1.3191Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China. Annals of Hematology, 0, ,.1.8092(i>MPL) gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan. Hematology, 2023, 28, .1.5293The atherogenic index of plasma complicates the thrombotic tendency of chronic myeloproliferative disorders: A retrospective cohort study. 2023, 3, 54-61.0	87	Prognostication in myeloproliferative neoplasms, including mutational abnormalities. Blood Research, 2023, 58, S37-S45.	1.3	1
89(scp>ABOBPITBit is hournal of Haematology, 2023, 202, 699-703.2.5490Molecular findings in myeloid neoplasms. International Journal of Laboratory Hematology, 2023, 45, 442-448.1.3191Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China. Annals of Hematology, 0,,1.8092 <i>&gt;&gt;&gt; MPL</i> > gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan. Hematology, 2023, 28,.1.5293The atherogenic index of plasma complicates the thrombotic tendency of chronic myeloproliferative disorders: A retrospective cohort study., 2023, 3, 54-61.0	88	Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology. Cells, 2023, 12, 946.	4.1	2
90Molecular findings in myeloid neoplasms. International Journal of Laboratory Hematology, 2023, 45, 442-448.1.3191Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China. Annals of Hematology, 0, , .1.8092 <i>&gt;MPL</i> > gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan. Hematology, 2023, 28, .1.5293The atherogenic index of plasma complicates the thrombotic tendency of chronic myeloproliferative disorders: A retrospective cohort study. , 2023, 3, 54-61.0	89	<scp>ABO</scp> blood group type and risk of venous thrombosis in essential thrombocythemia. British Journal of Haematology, 2023, 202, 699-703.	2.5	4
91Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China. Annals of Hematology, 0, , .1.8092 <i>MPL</i> gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan. Hematology, 2023, 28, .1.5293The atherogenic index of plasma complicates the thrombotic tendency of chronic myeloproliferative disorders: A retrospective cohort study. , 2023, 3, 54-61.0	90	Molecular findings in myeloid neoplasms. International Journal of Laboratory Hematology, 2023, 45, 442-448.	1.3	1
92 <i>&gt;MPL</i> gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan. Hematology, 2023, 28, .1.5293The atherogenic index of plasma complicates the thrombotic tendency of chronic myeloproliferative disorders: A retrospective cohort study. , 2023, 3, 54-61.0	91	Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China. Annals of Hematology, 0, , .	1.8	0
93The atherogenic index of plasma complicates the thrombotic tendency of chronic myeloproliferative disorders: A retrospective cohort study. , 2023, 3, 54-61.0	92	<i>MPL</i> gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan. Hematology, 2023, 28, .	1.5	2
	93	The atherogenic index of plasma complicates the thrombotic tendency of chronic myeloproliferative disorders: A retrospective cohort study. , 2023, 3, 54-61.		0

#	Article	IF	CITATIONS
94	Pathologies hématologiques. , 2022, , 313-373.		0
95	Essential Thrombocythemia and Ischemic Stroke: A Case Series of Five JAK2-Positive Patients. Medicina (Lithuania), 2023, 59, 1300.	2.0	0
96	Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group. Clinical and Experimental Medicine, 2023, 23, 4199-4217.	3.6	0
97	Treatment Algorithm of Essential Thrombocythemia. , 2023, , 523-538.		0
98	Diagnosis and Management of Prefibrotic Primary Myelofibrosis (Pre-PMF). , 2023, , 549-557.		0
99	Impact of nonâ€driver gene mutations on thromboâ€haemorrhagic events in <scp>ET</scp> patients. British Journal of Haematology, 0, , .	2.5	0
100	Molecular diagnostic criteria of myeloproliferative neoplasms. Expert Review of Molecular Diagnostics, 2023, 23, 1077-1090.	3.1	0
101	Correlation between IPSET-t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience. Annals of Hematology, 0, , .	1.8	1
102	One thousand patients with essential thrombocythemia: the Mayo Clinic experience. Blood Cancer Journal, 2024, 14, .	6.2	3
103	One thousand patients with essential thrombocythemia: the Florence-CRIMM experience. Blood Cancer Journal, 2024, 14, .	6.2	3
104	Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2024, 99, 697-718.	4.1	1
105	Case report: Peri-procedural hydroxyurea helps minimize bleeding in patients with Essential Thrombocythemia associated with acquired von Willebrand syndrome. Frontiers in Oncology, 0, 14, .	2.8	0
106	A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery. Cureus, 2024, , .	0.5	0

CITATION REPORT